X4 Pharmaceuticals, Inc. Common Stock
$3.50
-$0.01 (-0.43%)
$3.41Day Range$3.58
Key Statistics
Market Cap
$348.01M
Shares Outstanding
99.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 16, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$3.56
Day High
$3.58
Day Low
$3.41
Volume
406.9K
VWAP
$3.49
Prev Close
$3.51
Transactions
--
Acc. Volume
--
About X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283645 employees61 NORTH BEACON STREET, BOSTON, MA, 02134857-529-8300IPO Nov 16, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001501697
- Composite FIGI
- BBG001J1CYH8
- Share Class FIGI
- BBG001TCY1B7
- Ticker Root
- XFOR
- SIC Code
- 2836
About X4 Pharmaceuticals, Inc. Common Stock (XFOR) Stock
X4 Pharmaceuticals, Inc. Common Stock (XFOR) closed the 2026-09-17 session at $3.50, down 0.43% versus the previous close (-0.01). The stock opened at $3.56 and traded between $3.41 and $3.58 during that session. Session trading volume was 407K shares. The volume-weighted average price (VWAP) is $3.49.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
X4 Pharmaceuticals, Inc. Common Stock has a market capitalization of $348.0 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. XFOR is listed on the XNAS exchange. The company employs approximately 45 people. X4 Pharmaceuticals, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2017-11-16.
On this page you can find market XFOR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.